Medical device maker Medtronic is looking at options to modify its global manufacturing footprint as part of efforts to ...

After decades of development and trials, Medtronic has secured U.S. Food and Drug Administration approval for adaptive ...

The U.S. Food and Drug Administration has approved Medtronic's deep brain stimulation system for use in patients with ...

The FDA’s authorisation of Medtronic’s BrainSense follows the system’s receipt of a CE mark in Europe last month.

Medtronic received Food and Drug Administration approval for the BrainSense Adaptive deep brain stimulation (DBS) device for ...

Truist Financial analyst Richard Newitter maintained a Hold rating on Medtronic (MDT – Research Report) on February 23 and set a price target ...

Medtronic on Tuesday missed Wall Street estimates for third-quarter revenue due to lower purchases of its surgical devices by ...

Shortly after obtaining a greenlight in Europe and after more than 10 years in development, Medtronic has now received the ...

Shares of Medtronic ( MDT -6.63%) were sinking 7.3% as of 11:21 a.m. ET on Tuesday. The decline came after the medical device ...

Medtronic's stock is probably not a jaw-dropping bargain at these prices, but it's an excellent business at a reasonable value. It's safe to call Medtronic a solid buy, especially if you're a ...

The FDA approved Medtronic's BrainSense Adaptive DBS and Electrode Identifier for Parkinson's, enhancing therapy ...

Medtronic (MDT) announced FDA approval of BrainSense Adaptive deep brain stimulation – aDBS – and BrainSense Electrode Identifier. There is no ...